ADPRS Knockout cell line (HCC1806)

CRISPR knockout cell lines are engineered through targeted genome editing to eliminate gene function, supporting studies of cellular biology, disease mechanisms, and drug discovery.

APOBEC3A_B (APOBEC3A and APOBEC3B deletion hybrid) encodes a hybrid protein associated with antiviral defense and restriction of foreign DNA. The protein is equivalent to that encoded by APOBEC3A but arises from a deletion spanning the adjacent APOBEC3A and APOBEC3B genes. Although it lacks the zinc-binding activity characteristic of other family members, it can restrict foreign DNA through mechanisms that may include cytidine deamination and DNA degradation, as well as deaminase-independent antiviral effects.

The HCC1806 breast cancer cell line was initiated on July 31, 1995, and required a periods of 10 months to be fully established. Characterized as a reliable human in vitro model, HCC1806 is extensively applied in oncology research to investigate the underlying mechanisms of breast cancer progression, tumor cell proliferation, and to evaluate the efficacy of novel therapeutic compounds during drug screening.

Before delivery, each clone is authenticated by STR, tested for sterility and mycoplasma, and genotype‑verified by two‑round PCR‑sequencing. Comprehensive QC data accompany every shipment to support reproducible research.